INTERNATIONAL SEARCH REPORT

International application No.

		PCT/UPZ	004/013982
A. CLASSIFIC. Int.Cl ⁷	ATION OF SUBJECT MATTER A61K31/195, 31/216, 31/4365, 3 A61P7/02, 9/04, 9/10, 11/00,	31/519, 31/616, 45/00, 43/00	
According to Inte	mational Patent Classification (IPC) or to both national	classification and IPC	
B. FIELDS SEA	ARCHED		
Minimum docum	entation searched (classification system followed by class	sification symbols)	
Int.Cl ⁷	A61K31/195, 31/216, 31/4365, 3 A61P7/02, 9/04, 9/10, 11/00,	31/519, 31/616, 45/00, 43/00	
	earched other than minimum documentation to the exten		
Electronic data be REGISTF	ase consulted during the international search (name of da RY (STN), CAPLUS (STN), MEDLINE (ST	ata base and, where practicable, search ter	rms used)
C. DOCUMEN	TS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where app	·	Relevant to claim No.
Y	WO 2002/028827 Al (Kissei Pha Ltd.),	ermaceutical Co.,	1-9
	11 April, 2002 (11.04.02), All references; particularly, 11, 12; page 28, lines 16 to	Claims 3 to 7, 9, last line;	
	examples 8, 11, 18 to 20 & EP 1331221 A1	a autical Ca	. 1–9
Y	JP 2003-104957 A (Kissei Pharmaceutical Co., Ltd.), 09 April, 2003 (09.04.03), Particularly, Par. Nos. [0002], [0051] to [0053] (Family: none)		1-9
	ocuments are listed in the continuation of Box C.	See patent family annex.	
"A" document defining the general state of the art which is not considered to be of particular relevance		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international "X filing date		"X" document of particular relevance; the considered novel or cannot be considered novel or cann	idered to involve an inventive
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is	
"O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed		combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 07 December, 2004 (07.12.04)		Date of mailing of the international search report 28 December, 2004 (28.12.04)	
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer	
Facsimile No.	210 (second sheet) (January 2004)	Telephone No.	
LOUILI CI/IONZ	to (necessary process) (contemp) model)		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/013982

PCT/J		P2004/013982	
). DOCUMENTS CONSIDERED TO BE RELEVANT			
Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
WO 2003/000256 A1 (BAYER HEALTHCARE AG, DE), 03 January, 2003 (03.01.03), Particularly, page 1, lines 9 to 25; page 32, lines 1 to 18; page 40, lines 1 to last line & DE 10129725 A1		1-9	
		1-9	
JP 8-217692 A (Nippon Steel Corp., Nippon Chemical Co., Ltd.), 27 August, 1996 (27.08.96), Particularly, Par. No. [0005] (Family: none)	Steel	1-9	
JP 9-20681 A (Behringwerke AG.), 21 January, 1997 (21.01.97), Particularly, Par. Nos. [0003] to [0004] & EP 732102 A2		1-9	
JP 7-258103 A (Kyo Keisei), 09 October, 1995 (09.10.95), Particularly, Par. Nos. [0049], [0064]; paring 7 Fig. 7 & DE 4432549 A1 & KR 9711555 B1	age 12,	1-9	
Adrienne R., Antithrombotic actions of settive inhibitors of blood coagulation factors as in rat models of thrombosis, Thrombosis Research, 1996, Vol.83, No.2, pages 117 to 126, particularly, page 118, lower part to	lec or is o	1-9	
to Tsukaikata", Medical Practice, 2002, Vo	01.19,	1-9	
	Citation of document, with indication, where appropriate, of the relevant WO 2003/000256 A1 (BAYER HEALTHCARE AG, DOS) January, 2003 (03.01.03), Particularly, page 1, lines 9 to 25; page lines 1 to 18; page 40, lines 1 to last 15 & DE 10129725 A1 JP 2002-504110 A (SANOFI-SANTE LABO.), 05 February, 2002 (05.02.02), Particularly, Claims; page 7, lines 2 to 6 page 77, line 21 to page 79, line 1; page Fig. 1 & US 6541488 B1 JP 8-217692 A (Nippon Steel Corp., Nippon Chemical Co., Ltd.), 27 August, 1996 (27.08.96), Particularly, Par. No. [0005] (Family: none) JP 9-20681 A (Behringwerke AG.), 21 January, 1997 (21.01.97), Particularly, Par. Nos. [0003] to [0004] & EP 732102 A2 JP 7-258103 A (Kyo Keisei), 09 October, 1995 (09.10.95), Particularly, Par. Nos. [0049], [0064]; par	Citation of document, with indication, where appropriate, of the relevant passages WO 2003/000256 A1 (BAYER HEALTHCARE AG, DE), 03 January, 2003 (03.01.03), Particularly, page 1, lines 9 to 25; page 32, lines 1 to 18; page 40, lines 1 to last line & DE 10129725 A1 JP 2002-504110 A (SANOFI-SANTE LABO.), 05 February, 2002 (05.02.02), Particularly, Claims; page 7, lines 2 to 6; page 77, line 21 to page 79, line 1; page 84, Fig. 1 & EP 986376 A1 & US 6541488 B1 JP 8-217692 A (Nippon Steel Corp., Nippon Steel Chemical Co., Ltd.), 27 August, 1996 (27.08.96), Particularly, Par. No. [0005] (Family: none) JP 9-20681 A (Behringwerke AG.), 21 January, 1997 (21.01.97), Particularly, Far. Nos. [0003] to [0004] & EP 732102 A2 JP 7-258103 A (Kyo Keisei), 09 October, 1995 (09.10.95), Particularly, Par. Nos. [0049], [0064]; page 12, Fig. 7 & DE 4432549 A1 & KR 9711555 B1 Pancras C.W., Earl J.C., Oliver N., Carol A.W., Adrienne R., Antithrombotic actions of selective inhibitors of blood coagulation factor X a in rat models of thrombosis, Thrombosis Research, 1996, Vol.83, No.2, pages 117 to 126, particularly, page 118, lower part to page 119, line 12, Arterio-venous shunt model, page 121, Fig. 2 Yasuo IKEDA, "Kokeshobanyaku no Rinsho Koka to Tsukaikata", Medical Practice, 2002, Vol.19, No.5, pages 839 to 844, particularly, pages 843	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)